Household contact as a key risk factor for latent tuberculosis infection among patients with diffuse large B-cell lymphoma
DOI:
https://doi.org/10.69898/jhtm.35.2025.276052Keywords:
latent tuberculosis infection, diffuse large B-cell lymphoma, risk factorAbstract
Introduction: Patients with diffuse large B-cell lymphoma (DLBCL) have an increased risk of reactivating latent tuberculosis infection (LTBI) into active tuberculosis (TB) during chemotherapy or hematopoietic stem cell transplantation. However, extensive testing for LTBI among all patients is not practical, especially in regions with limited health resources. Objective: This study aimed to identify risk factors associated with an increased risk of LTBI among patients with newly diagnosed DLBCL and to determine the prevalence of LTBI in these patients. Materials and Methods: A retrospective cohort study of patients with newly diagnosed DLBCL was conducted at Ching Rai Prachanukroh Hospital from September 2020 to June 2023. All patients were screened for LTBI using interferon-release assays (IGRAs), either the QuantiFERON-TB Gold In-Tube (QFT) or T-SPOT.TB (T-SPOT) tests, after DLBCL diagnosis and before the start of treatment. Data were collected from medical records. Generalized linear models were used to estimate the adjusted risk ratio (RR) and 95% confidence interval (CI) for LTBI risk factors. Results: A total of 127 patients with newly diagnosed DLBCL were enrolled, with a mean age of 59.17 years. Among them, 17 patients had IGRAs-proven LTBI, resulting in an prvalence of 13.39%. The results showed that household contact with TB significantly increased the risk of LTBI (adjusted RR: 3.24, 95% CI: 1.51-6.14). Conclusion: Patients with newly diagnosed DLBCL patients who had household contact with TB had a significantly higher risk of LTBI. These findings highlight the importance of targeted LTBI screening among patients with newly diagnosed DLBCL, particularly those with household contact with TB.
Downloads
References
Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet. 2019;393:1331-84.
Global tuberculosis report 2024. Geneva: World Health Organization; 2024.
Division of Tuberculosis. National Tuberculosis Control Programme Guideline, Thailand 2021. Bangkok: Division of Tuberculosis; 2021.
Report on the situation of tuberculosis. Chiang Rai Provincial public health. 2024
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33:956-73.
Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-86.
Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2015.
Gatechompol S, Harnpariphan W, Supanan R, Suwanpimolkul G, Sophonphan J, Ubolyam S, et al. Prevalence of latent tuberculosis infection and feasibility of TB preventive therapy among Thai prisoners: a cross-sectional study. BMC Public Health. 2021;21:1206.
Nonghanphithak D, Reechaipichitkul W, Chaiyasung T, Faksri K. Risk factors for latent tuberculosis infection among health-care workers in Northeastern Thailand. Southeast Asian J Trop Med Public Health. 2016;47:1198-1208.
Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2023.
Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99:131-8.
Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of Malnutrition. Trends Immunol. 2016;37:386-98.
Dobler CC, Cheung K, Nguyen J, Martin A. Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J. 2017;50:1700157.
Anibarro L, Pena A. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis. 2014;6:e2014026.
Ganzel C, Silverman B, Chemtob D, Ben Shoham A, Wiener-Well Y. The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study. Leuk Lymphoma. 2019;60:720-5.
Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, Switzerland: World Health Organization; 2018.
Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland: World Health Organization; Guidelines update date: 2020.
Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung. 2013;191:565-71.
Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva, Switzerland: World Health Organization. 2012.
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: World Health Organization. 2011.
Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K, et al. Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. Hematol Oncol. 2018;36:28-36.
Cheon J, Kim C, Park EJ, Ock M, Lee H, Ahn JJ, et al. Active tuberculosis risk associated with malignancies: an 18-year retrospective cohort study in Korea. J Thorac Dis. 2020;12:4950-9.
Chen CY, Sheng WH, Cheng A, Tsay W, Huang SY, Tang JL, et al. Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infect Dis. 2011;11:324.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90.
Jonas DE, Riley SR, Lee LC, Coffey CP, Wang SH, Asher GN, et al. Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;329:1495-1509.
Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563-76.
Mortezazadeh M, Karimi M, Esfandbod M, Mofidi A, Hemmati N, Kashani M, et al. Investigation of the prevalence of latent tuberculosis in cancer patients compared to non-cancer patients: a case-control study. Oncol Rev. 2024;18:1445678.
Bourlon C, Camacho-Hernández R, Fierro-Angulo OM, Acosta-Medina AA, Bourlon MT, Niembro-Ortega MD, et al. Latent Tuberculosis in Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Strategies to Prevent Disease Activation in an Endemic Population. Biol Blood Marrow Transplant. 2020;26:1350-4.
Osorio-López EA, Vilar-Compte D, García-Tirado J, Martin-Onraet A. Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City. BMC Infect Dis. 2021;21:510.
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3-20.
Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761-6.
Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016;13:e1002152.
Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;64:635-44.
Auguste P, Tsertsvadze A, Pink J, Court R, McCarthy N, Sutcliffe P, et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infect Dis. 2017;17:200.
González-Moreno J, García-Gasalla M, Losada-López I, Cifuentes Luna C, Mir Viladrich I, Fernández-Baca V, et al. IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results? Rheumatol Int. 2018;38:267-73.
Rao M, Ippolito G, Mfinanga S, Ntoumi F, Yeboah-Manu D, Vilaplana C, et al. Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground. Int J Infect Dis. 2019;80S:S58-S61.
Karbito K, Susanto H, Adi MS, Sulistiyani S, Handayani OWK, Sofro MAU. Latent tuberculosis infection in family members in household contact with active tuberculosis patients in Semarang City, Central Java, Indonesia. J Public Health Afr. 2022;13:2157.
Faiz JF, Hadi EN. Risk Factors for Latent Tuberculosis Infection (LTBI) Among Household contacts with TB Patients: A Systematic Review. JIKM [Internet]. 2024;15:288-302.
Tornee S, Kaewkungwal J, Fungladda W, Silachamroon U, Akarasewi P, Sunakorn P. Risk factors for tuberculosis infection among household contacts in Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 2004;35:375-83.
Lee SJ, Lee SH, Kim YE, Cho YJ, Jeong YY, Kim HC, et al. Risk factors for latent tuberculosis infection in close contacts of active tuberculosis patients in South Korea: a prospective cohort study. BMC Infect Dis. 2014;14:566.
Sayuti NASA, Ibrahim FW, Jufri NF, Masre SF, Abdullah AHA, Raub SHA, et al. Retrospective data analysis on the prevalence and demographic risk factors for latent tuberculosis infection (LTBI) cases from a private laboratory in Malaysia. Trop Biomed. 2024;41:257-63.
Nababan B, Triasih R, Chan G, Dwihardiani B, Hidayat A, Dewi SC, et al. The Yield of Active Tuberculosis Disease and Latent Tuberculosis Infection in Tuberculosis Household Contacts Investigated Using Chest X-ray in Yogyakarta Province, Indonesia. Trop Med Infect Dis. 2024;9:34.
Djibougou DA, Mensah GI, Sagna T, Sawadogo LT, Ouedraogo AK, Kabore A, et al. Magnitude and associated factors of latent tuberculosis infection due to Mycobacterium tuberculosis complex among high-risk groups in urban Bobo-Dioulasso, Burkina Faso. IJID Reg. 2022;4:1-9.
Ncayiyana JR, Bassett J, West N, Westreich D, Musenge E, Emch M, et al. Prevalence of latent tuberculosis infection and predictive factors in an urban informal settlement in Johannesburg, South Africa: a cross-sectional study. BMC Infect Dis. 2016;16:661.
Katelaris AL, Jackson C, Southern J, Gupta RK, Drobniewski F, Lalvani A, et al. Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort. J Infect Dis. 2020;221:146-55.
Wang PH, Lin SY, Liou HH, Chen CC, Shu CC, Lee CY, et al. Protective Effect of BCG and Neutrophil-to-Lymphocyte Ratio on Latent Tuberculosis in End Stage Renal Disease. Infect Dis Ther. 2023;12:1907-20.
Huang W, Fang Z, Luo S, Lin S, Xu L, Yan B, et al. The effect of BCG vaccination and risk factors for latent tuberculosis infection among college freshmen in China. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2022;122:321-26
Chanpho P, Chaiear N, Kamsa-Ard S. Factors Associated with Latent Tuberculosis Infection among the Hospital Employees in a Tertiary Hospital of Northeastern Thailand. Int J Environ Res Public Health. 2020;17:6876.
Dockrell HM, Smith SG. What Have We Learnt about BCG Vaccination in the Last 20 Years? Front Immunol. 2017;8:1134.
Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3:656-62.
Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol Assess. 2013;17:1-372, v-vi.
Implementing the end TB strategy: the essentials, 2022 update. Geneva: World Health Organization; 2022.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
